MELBOURNE, April 27, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research has unveiled a new report called "Immuno-Oncology (IO) Market" which provides an in-depth exploration of growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and the competitive landscape. A worldwide Immuno-Oncology (IO) market report brings into focus plenty of factors such as the general market conditions, trends, inclinations, key players, opportunities, and geographical analysis which all aid to take the business towards growth and success. The increasing prevalence of this market report highlights the major industry growth drivers, challenges, opportunities, and restraints for the leading key players. The report provides the broader perspective of the marketplace with its comprehensive market insights and analysis which eases surviving and succeeding in the market. Hence, Immuno-Oncology (IO) document brings into the focus, more important aspects of the market or Immuno-Oncology (IO) industry.
With a devotion and commitment to a supreme level of resilience and integrated approaches, the top-notch Immuno-Oncology (IO) business research report has been prepared. The market report also identifies and analyses the emerging trends along with major driving factors, challenges, and opportunities in the market. This industry analysis report also provides CAGR value fluctuation in percentage during the forecast period of 2023-2030 for the market. The large-scale Immuno-Oncology (IO) market survey report comprises of extensive study of diverse market segments and regions, emerging trends along with major drivers, challenges, and opportunities in the market.
Data Bridge Market Research analyses that the immuno-oncology (IO) market, which is USD 28.10 billion in 2022, is expected to reach USD 156.05 billion by 2030, at a CAGR of 23.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Get a Sample PDF of the Immuno-Oncology (IO) Market Research @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-oncology-market
Immuno-Oncology (I-O) is an advanced area of research that seeks to help the body's immune system fight cancer. Drugs used for cancer treatment enhance or suppress the immune system to support the body's defenses against cancer, infections, and other diseases. To boost the immune system and help the body find and get rid of cancer cells, it uses substances created by the body or in a lab.
Government approval for cytokines, vaccines, tumor-directed monoclonal antibodies, immune checkpoint blockers, and other IO medications has contributed to substantial advancements in IO in recent years. The market is anticipated to increase as more people become aware of the benefits of IO over traditional approaches. In contrast to merely treating cancer, IO therapies stimulate the immune system, which helps to address a larger patient population. This will open up new potential for the industry's expansion throughout the forecast period.
The Global Market Is Analyzed in Depth in the Latest Study. Taking into account the current level of competition and its projected evolution over the next few years.
Rapidly increasing demands, a rise in industrialization, consumer awareness, growing sectors, and technical improvements are fueling the expansion of the global Immuno-Oncology (IO) market. Sales and revenue in this sector have increased at an exponential rate. The market's size and growth are both expected to increase thanks to the factors driving the market's expansion over the projected period.
Leading businesses in the worldwide Immuno-Oncology (IO) market are investing heavily in R&D in order to build a larger client base and expand their share of the market by reintroducing improved products to consumers. All of the companies' strategy, as well as their financial health, revenue, gross margin, and growth rate, are detailed in the study.
Opportunities:
- Collaboration and partnerships are a promising opportunity
Companies have long collaborated with academic and research organizations in this industry for a long time through partnerships and in- or out-licensing agreements, and this trend has been accelerating in recent years. For instance, in September 2020, the US-based biopharmaceutical company AbbVie, Inc., which specializes in drug discovery, research, and development, announced its research partnership with I-Mab Biopharma Co. Ltd. This Chinese biopharmaceutical company has made significant advancements in the discovery, development, and commercialization of biological drugs for immunology. Together, the two companies will focus on developing Lemzoparlimab (also known as TJC4), a novel anti-CD47 monoclonal antibody that I-Mab separately discovered and developed to treat a variety of malignancies. The agreement covers its commercialization and development. Additionally, the two parties could opt to continue working together.
The Immuno-Oncology (IO) industry is primarily led by companies like
- Bristol Myers Squibb Company (US.)
- Novartis AG (Switzerland)
- F. Hoffmann-LA Roche Ltd. (Switzerland)
- Merck & Co., Inc. (U.S.)
- GSK Plc. (UK.)
- Eli Lilly and Company (US.)
- Fresenius Kabi AG (Germany)
- Pfizer Inc. (US.)
- AbbVie Inc. (US.)
- Genentech Inc. (U.S.)
- Sanofi (France)
- AstraZeneca (UK.)
Recent Development
In 2021, Amunix Pharmaceuticals, Inc. was acquired by Sanofi SA, a biopharmaceutical and healthcare organization with its headquarters in France, for $1 billion. With the help of this acquisition, Sanofi is better able to develop novel treatments for cancer patients, conduct research on immune-oncology therapeutic candidates, find new drugs, bring these potentially better and safer treatment options to patients by collaborating as a center of excellence, and expand its oncology pipeline.
Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-immuno-oncology-market
Our market intelligence platform provides a range of benefits that will help you gain valuable insights and stay ahead in the market. By utilizing our platform, you can:
- Identify emerging market trends and dynamics
- Access high-quality and accurate market intelligence
- Explore competitive strategies and analyze market share
- Discover regional market opportunities that may have been overlooked
- Choose from multiple deliverable formats, including PDF, PPT, Excel, and an online dashboard
With our comprehensive market intelligence platform, you can easily access the information you need to make informed decisions and stay ahead of the competition.
At Data Bridge Market Research, we employ a comprehensive and iterative research methodology aimed at minimizing deviations to provide the most accurate estimates and forecasts possible. Our approach involves utilizing both bottom-up and top-down methods to segment and estimate the quantitative aspects of the market. Furthermore, a recurring theme across all our research reports is data triangulation, which examines the market from three distinct perspectives.
To derive our market estimates and forecasts, we employ simulation models that are tailored for each study. We gather information on market dynamics, technology landscape, application development, and pricing trends, which are then fed into the model and analyzed simultaneously. We compare these factors and quantify their impact on the forecast period using correlation, regression, and time series analysis. Our market forecasting is performed using a combination of economic tools, technological analysis, and our team's industry experience and domain expertise.
Key Market Segments Covered in Immuno-Oncology (IO) Industry Research
Type
- Monoclonal Antibodies
- Checkpoint Inhibitors
- Cytokines
Targets
- IDO1i
- Oncolytic virus
- STING agonist
- TLR agonist
- TIL
- MEKi
- TIGIT
- CPI
- GITR agonist
- TGF-b trap
- A2AR antagonist/CD73i
- LAG-3
- Anti-CTLA-4
- MAGE-A3, VEGF
- HDAC
- STING
- TIM-3
- TGF-Beta
- OX40
Indication
- Malignant Tumors
- Benign Tumors
End Users
- Hospitals
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Key Industry Drivers:
- The rise in cancer cases will bolster the market growth
The market for immuno-oncology drugs is projected to expand due to the increase in cancer diagnoses worldwide. For instance, the American Cancer Society predicts that there will be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US in January 2022, or about 1,670 fatalities every day. Lung, prostate, bowel, and female breast cancer are the top four cancer types globally, making up 43% of all new cancer cases. Lung, prostate, bowel, and female breast cancer account for 43% of all new instances of cancer, making them the four most prevalent cancers worldwide. Therefore, it is projected that the rise in cancer incidence rates worldwide will increase the demand for immune-oncology medications.
- Rising research and development funding will propel the market growth
Research and development funding is heavily invested in the fight against cancer, particularly precision medicine. Based on a person's genetic profile, precision medicine offers them individualized care. Consequently, the future of cancer treatment is likely to involve a combination of immunotherapy and personalized therapy. Better patient outcomes will surely be observed across a wide range of cancer types due to the advances in cancer management backed by the most recent surgical and radiation technology. These are the certain factors that propel the market growth.
Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-immuno-oncology-market
Immuno-Oncology (IO) Market Regional Analysis/Insights:
The countries covered in the immuno-oncology (IO) market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the immuno-oncology (IO) market as a result of the disease's rising occurrence. The region's immuno-oncology (IO) market will also experience increased expansion due to the expanding accessibility of contemporary therapies.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the uptake of cancer immunotherapy is expanding at a good rate. Additionally, it is expected that the immuno-oncology (IO) market will develop in the region in the upcoming years due to the rise in disease incidence and, consequently, the rising death rate.
Some of the Most Important Questions Scrutinized in the Business Intelligence Report:
What are the key growth parameters for this global market during the forecast period?
Which key players are expected to hold the largest market share over the forecast period?
Who are the leading vendors and manufacturers in this market?
What are the key strategies adopted by leading players in the market for business development and geographical expansion?
Which end-use industries can trigger high demand in the market over the forecast period?
What are the key segments in this market?
Which regional player will anticipated leading the global market in terms of size?
What is the impact of novel coronavirus pandemic?
Which obstacles must new players overcome in order to occupy a major position?
Table of Contents:
- Introduction
- Market Segmentation
- Executive Summary
- Premium Insights
- Global Immuno-Oncology (IO) Market: Regulations
- Market Overview
- Global Immuno-Oncology (IO) Market, By Type
- Global Immuno-Oncology (IO) Market, By Targets
- Global Immuno-Oncology (IO) Market, By Indication
- Global Immuno-Oncology (IO) Market, By End User
- Global Immuno-Oncology (IO) Market, By Distribution Channel
- Global Immuno-Oncology (IO) Market, By Region
- Global Immuno-Oncology (IO) Market: Company Landscape
- SWOT Analyses
- Company Profile
- Questionnaires
- Related Reports
Download the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-immuno-oncology-market
Explore More Reports:
- Immuno-Oncology Clinical Trials Market, By Phase (Phase I, Phase I, Phase III, Phase IV), Design (Interventional Trials, Observational Trials, Expanded Access Trials), Indication (Solid Tumours, Hematological Cancer), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-immuno-oncology-clinical-trials-market
- Oncology Nutrition Market, By Cancer Type (Head and Neck Cancer, Stomach and Gastrointestinal Cancers, Esophageal Cancer, Pancreatic Cancer, Liver Cancer, Blood Cancer, Breast Cancer, Lung Cancer, Others), Nutrition (Enteral Nutrition, Parenteral Nutrition), Formula (Standard Formula, Elemental Formula, Specialized Formula), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029 https://www.databridgemarketresearch.com/reports/global-oncology-nutrition-market
- Interventional Oncology Devices Market, By Product Type (Embolization Devices, Ablation Devices, Support Devices, Next-Gen Devices), Cancer Type (Liver Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Bone Cancer, Kidney Cancer, Others), Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, Transcatheter Arterial Embolization/Bland Embolization), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast https://www.databridgemarketresearch.com/reports/global-interventional-oncology-devices-market
- Hematology Oncology Market, By Hematology Product (Hematology Analyzers, Hematology Reagents, Flow Cytometers, Hematology Cell Counters, Slide Strainers, Coagulation Analyzers, Hematology Testing, Centrifuges, Hemoglobin meters, Others), Oncology Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), Oncology Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others), Applications (Infectious Diseases, Cancer, Cardiovascular Disorders, Blood Screening, Diabetes, HIV, Auto – Immune Diseases), End Users (Hospitals, Clinical Testing Institutes, Patient Self- Testing, Other End- Users) https://www.databridgemarketresearch.com/reports/global-hematology-oncology-market
- Hemato Oncology Testing Market, By Product and Services (Services, Assay Kits), Cancer Type (Leukemia, Lymphoma, Other Cancers), Technology (PCR, IHS, NGS, Cytogenetics, Other), End Users (Clinical Laboratories, Hospitals, Academic and Research Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-hemato-oncology-testing-market
- Oncology Clinical Trial Monitor Market, By Phase (Phase I, Phase II, Phase III, Phase IV), Study Design (Interventional, Observational, Expanded Access), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-oncology-clinical-trial-monitor-market
- Oncology Biosimilars Market, By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) https://www.databridgemarketresearch.com/reports/global-oncology-biosimilars-market
- Clinical Oncology Next Generation Sequencing Market, By Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing and Resequencing), Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), Application (Screening, Companion Diagnostics, Others), End User (Hospitals, Clinics, Laboratories, Others) https://www.databridgemarketresearch.com/reports/global-clinical-oncology-next-generation-sequencing-market
- Oncology Information Systems Market, By Products and Services (Solutions, Professional Services), By Application (Medical Oncology, Surgical Oncology) https://www.databridgemarketresearch.com/reports/global-oncology-information-systems-market
- Radiation Oncology Treatment Planning Software Market, By Product and Services (Software, Patient Information Systems, Treatment Planning System, Professional Services, Consulting/Optimization Services, Implementation Services, Post-Sale and Maintenance Services), Therapy Type (Stereotactic Radiosurgery (SRS), 3-D Conformal Radiation Therapy (3D CRT), Brachytherapy, Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT),Others, End-User (Hospitals and Physician’s Offices, Research Centers, Government Institutions, Cancer Treatment Centres, Others) https://www.databridgemarketresearch.com/reports/global-radiation-oncology-treatment-planning-software-market
- Oncology Molecular Diagnostic Market, By Type (Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, Others), Product (Instruments, Reagents, Others), Test Location (Clinics and Other Establishments, Point of Care), Technology (PCR, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification, Others), End User (Hospitals, Diagnostic Centers) https://www.databridgemarketresearch.com/reports/global-oncology-molecular-diagnostic-market
- Immuno Oncology Assays Market, By Product Type (Consumables, Software), Technology (Next Generation Sequencing, Flow Cytometry, PCR, Others), Indication (Lung Cancer, Colorectal Cancer, Melanoma, Leukemia, Lymphoma, Multiple Myeloma, Bladder Cancer, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-immuno-oncology-assays-market
- Veterinary Oncology Market, By Animal Type (Companion Animal, Livestock Animal), Therapy Type (Surgery, Combination Therapy, Chemotherapy, Targeted Therapy, Radiology, Immunotherapy), Application (Melanoma, Osteosarcoma (OSA), Canine Lymphoma, Mast Cell Cancer, Multiple Myeloma), Route of Administration (Intravenous, Oral, Other), End-Users (Veterinary Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-veterinary-oncology-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
